Background Per cent slowing of decline is frequently used as a metric of outcome in Alzheimer’s disease (AD) clinical trials, but it may be misleading. Our objective was to determine whether per cent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback